Ground-breaking study may lead to accelerated sales pipeline for Nanosonics
Stockbroker
A ground-breaking new study has shown that Nanosonic's trophon is the ONLY ultrasound disinfection system able to kill the human papilloma virus (HPV). The predominate systems in the US use glutaraldehyde or OPA while sonographers in the UK and Europe typically use wipes-based systems. None of these systems appear to be effective against HPV. Other studies have shown that HPV can be detected on ultrasound probes after these procedures. Infection with HPV is responsible for nearly all cases of cervical cancers and is the leading cause of several other cancers. These data, in combination with the recently reported outbreak of CRE infections from duodenoscopes, which prompted an FDA review last week, are likely to increase the focus on how semi-critical medical equipment is cleaned and disinfected between patients. We maintain our BUY recommendation for NAN and have increased our DCF-based price target to $2.20 (previously $2.00) assuming a slightly more rapid uptake of trophon: (VIEW LINK)
4 topics
Canaccord Genuity Group is a leading independent, full-service financial services firm. Canaccord Genuity has been driven by an unwavering commitment to building lasting client relationships. We achieve this by generating value for our individual,...
Expertise
No areas of expertise
Canaccord Genuity Group is a leading independent, full-service financial services firm. Canaccord Genuity has been driven by an unwavering commitment to building lasting client relationships. We achieve this by generating value for our individual,...
Expertise
No areas of expertise